DHX9 and cancer: The findings suggest that Rha‐Nanobody (Nb) conjugates hold promise as a novel therapeutic strategy for the treatment of cetuximab‐resistant tumors by enhancing the innate Fc effector immunity and enhancing the recruitment of endogenous antibodies to promote cancer cell clearance by innate immune cells.